Search
Search Constraints
You searched for: Author/Creator Kibata, Kayoko- Kibata, Kayoko [remove] 6
- 615.39 2
- Blood Platelets -- Periodicals 2
- Blood platelets -- Periodicals 2
- 3rd-gen 3rd generation agent -- Adeno adenocarcinoma -- ALK anaplastic lymphoma kinase -- BEV bevacizumab -- BOR best overall response -- CBDCA carboplatin -- CDDP cisplatin -- CI confidence interval -- CR complete response -- DCR disease control rate -- DOR duration of response -- DTX docetaxel -- ECOG PS Eastern Cooperative Oncology Group performance status -- EGFR epidermal growth factor receptor -- EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor -- HR hazard ratio -- IHC immunohistochemistry -- irAE immune related adverse events -- JLCS Japan Lung Cancer Society -- mut (-) mutation-negative -- mut (+) mutation-positive -- N.R. not reached -- NSCLC non-small cell lung cancer -- ORR objective response rates -- OS overall survival -- PD progressive disease -- PD-L1 programmed death-ligand 1 -- PEM pembrolizumab -- PFS progression-free survival -- Platinum or Platin platinum agent -- PR partial response -- PS performance status -- PTX paclitaxel -- RAM ramucirumab -- SD stable disease -- SQ squamous cell carcinoma -- TKI tyrosine kinase inhibitor 1
- 616.079 1
- 616.994005 1
- 616.99424 1
- 616.99494005 1
- CCL17 -- dendritic cells -- platelets -- RANK ligand -- thymic stromal lymphopoietin 1
- CCL17 -- myeloid DCs -- OX40L -- statin -- thymic stromal lymphopoietin (TSLP) 1